Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Verastem (0LOV) Share Price & Analysis

3 Followers

0LOV Stock Chart & Stats

$8.68-$0.07(3.95%)
At close: 4:30 PM GMT
$7$8$9$10Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$8.50 - $8.76
52-Week Range
$3.44 - $10.67
Previous Close
$8.35
Volume
N/A
Average Volume (3M)
15.82K
Market Cap
$1.10B
Enterprise Value
$770.71M
Total Cash (Recent Filing)
$172.80M
Total Debt (Recent Filing)
$122.12M
Price to Earnings (P/E)
―
Beta
1.10
Next Earnings
Mar 18, 2027 (Est.)
EPS Estimate
-0.53
Last Dividend Ex-Date
Mar 15, 2022
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Commercial Revenue Growth

Rapid product-revenue growth, broader physician adoption, and stronger refill activity indicate that the commercial franchise is gaining traction beyond initial launch uptake. Improving persistence and account expansion can support a more durable revenue base and provide greater operating leverage as commercialization continues.

Funding Runway

The substantial financing and stated funding runway reduce near-term liquidity pressure while Verastem advances clinical programs and commercialization. This gives management time to pursue pivotal studies and develop revenue opportunities without relying immediately on another capital raise to sustain planned operations.

Pipeline And Regulatory Progress

FDA alignment on a pivotal pancreatic cancer trial and advancement of additional registration-directed studies strengthen the strategic value of the pipeline. Positive activity across several tumor types could diversify future growth and create multiple opportunities for clinical validation and regulatory progress.

Bears Say

Persistent Operating Losses

The company remains deeply unprofitable despite rapid revenue growth, showing that its current cost base still substantially exceeds commercial contribution. Continued large losses could delay breakeven, require ongoing financing, and limit the company’s ability to reinvest from internally generated earnings.

Heavy Cash Burn

Persistent and worsening negative operating and free cash flow means reported revenue has not yet translated into self-funded operations. The resulting dependence on external capital remains a durable constraint, particularly while research spending and clinical development activity are expanding.

Leverage And Dilution Risk

The thin equity cushion and sharply higher leverage reduce financial flexibility while the company continues to generate losses. If cash burn persists, Verastem may face refinancing, additional secured financing, or equity issuance, each of which could increase financial costs or dilute existing holders.

Verastem News

0LOV FAQ

What was Verastem’s price range in the past 12 months?
Verastem lowest share price was $3.44 and its highest was $10.67 in the past 12 months.
What is Verastem’s market cap?
Verastem’s market cap is $1.10B.
When is Verastem’s upcoming earnings report date?
Verastem’s next earnings report is estimated for Mar 18, 2027 (not yet confirmed), which is in 126 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Nov 05, 2026. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.473 by -$0.267.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem pays a dividend of $0.285 which represents an annual dividend yield of ―. See more information on Verastem dividends here
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -0.53.
How many shares outstanding does Verastem have?
Verastem has 126,014,800 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.473. Following the earnings report the stock price went down -11.453%.
Which hedge fund is a major shareholder of Verastem?
Hedge funds hold Verastem shares: the largest hedge-fund position in Verastem is 1,351,869,158 shares, and hedge funds increased their holdings by 1.9M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology